Skip to main content
Clinical Trials/NCT06231316
NCT06231316
Not yet recruiting
Not Applicable

Preventing Spinal Hypotension During Cesarean Birth With Two Initial Boluses of Norepinephrine

Assiut University0 sites100 target enrollmentMarch 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anesthesia
Sponsor
Assiut University
Enrollment
100
Primary Endpoint
The frequency of postspinal hypotension
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Examining the advantages associated with the utilization of noradrenaline in preventing spinal hypotension during cesarean births. This involves assessing the positive outcomes and potential benefits derived from incorporating noradrenaline into the medical approach.

Detailed Description

Spinal anesthesia is used during cesarean section to provide rapid onset and dense block of motor and sensory nerves, intraoperative analgesia, and help patients remain conscious (1,2).Hypotension is common during induction of spinal anesthesia for cesarean delivery (CD) (3).If not promptly treated, a decrease in blood pressure (BP) can have deleterious effects, which include maternal nausea, vomiting, dizziness, and cardiovascular instability as well as decreased uteroplacental blood flow with resultant fetal acidosis, hypoxia, and bradycardia.In the last decade, the α-agonist phenylephrine (PE) has been the vasopressor of choice for the prevention and treatment of spinal induced hypotension (4).To prevent and treat postspinal anesthesia hypotension during cesarean section, vasopressors are recommended. Vasopressors (especially potent α-adrenergic receptor agonists) help offset the decrease in arteriolar dilation and peripheral vascular resistance caused by sympathetic nerve blockade after spinal anesthesia and may be associated with decreased incidence of neonatal acidosis.(5,6). Norepinephrine is another vasopressor that was recently introduced in obstetric anesthesia (7). Norepinephrine is characterized by α-adrenergic agonistic activity in addition to a weak β-adrenergic agonistic activity; thus, norepinephrine is considered a vasopressor with minimal cardiac depressant effect(7).; these pharmacologic properties would make norepinephrine an attractive alternative to phenylephrine and ephedrine in obstetric anesthesia. Although the use of norepinephrine for prophylaxis against postspinal hypotension has shown promising results,(7,8) evidence is lacking on the optimum dose for norepinephrine infusion during cesarean delivery.

Registry
clinicaltrials.gov
Start Date
March 1, 2024
End Date
May 1, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mohammad Mousa Abd Elsadek Ahmed

Doctor

Assiut University

Eligibility Criteria

Inclusion Criteria

  • The subject is scheduled for elective cesarean section .
  • No obvious abnormalities in preoperative ECG, blood routine, electrolytes, and other tests.
  • ASA class 1-3.

Exclusion Criteria

  • Patients have body mass index (BMI) \>35 kg/m
  • Patients are known hypersensitivity to any of the drugs that would be used in the study. -
  • Severe cardiac, renal, lung, or liver diseases.
  • Eclampsia or preexisting hypertension (baseline systolic blood pressure ≥160 mmHg)
  • hemoglobin \<7 g/dL, or fetal distress.
  • Patients that are immunologically compromised.
  • Sleep apnea syndrome or difficult airway. 8.preexisting hypoxemia (Spo2\< 90 %).
  • Patient refusal.

Outcomes

Primary Outcomes

The frequency of postspinal hypotension

Time Frame: baseline

Assessment of how often blood pressure decreases following spinal anesthesia, crucial for proactive management in medical procedures.

Secondary Outcomes

  • Hemodynamic data(baseline)

Similar Trials